Brian M Bot
Brian M Bot
Fred Hutch Cancer Center
Verified email at - Homepage
Cited by
Cited by
The consensus molecular subtypes of colorectal cancer
J Guinney, R Dienstmann, X Wang, A De Reynies, A Schlicker, ...
Nature medicine 21 (11), 1350-1356, 2015
The mPower study, Parkinson disease mobile data collected using ResearchKit
BM Bot, C Suver, EC Neto, M Kellen, A Klein, C Bare, M Doerr, A Pratap, ...
Scientific data 3 (1), 1-9, 2016
Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes
FA Sinicrope, Q Shi, TC Smyrk, SN Thibodeau, R Dienstmann, J Guinney, ...
Gastroenterology 148 (1), 88-99, 2015
Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study
R Dienstmann, MJ Mason, FA Sinicrope, AI Phipps, S Tejpar, ...
Annals of Oncology 28 (5), 1023-1031, 2017
Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients withá…
DJ Sargent, CH K÷hne, HK Sanoff, BM Bot, MT Seymour, A De Gramont, ...
Journal of Clinical Oncology 27 (12), 1948, 2009
Integrated analysis of gene expression, CpG island methylation, and gene copy number in breast cancer cells by deep sequencing
Z Sun, YW Asmann, KR Kalari, B Bot, JE Eckel-Passow, TR Baker, ...
PloS one 6 (2), e17490, 2011
Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials
C FertÚ, M Fernandez, A Hollebecque, S Koscielny, A Levy, C Massard, ...
Clinical Cancer Research 20 (1), 246-252, 2014
Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with opená…
J Guinney, T Wang, TD Laajala, KK Winner, JC Bare, EC Neto, SA Khan, ...
The Lancet Oncology 18 (1), 132-142, 2017
Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors
R Dienstmann, IS Jang, B Bot, S Friend, J Guinney
Cancer discovery 5 (2), 118-123, 2015
Mobile health: the power of wearables, sensors, and apps to transform clinical trials
B Munos, PC Baker, BM Bot, M Crouthamel, G de Vries, I Ferguson, ...
Annals of the New York Academy of Sciences 1375 (1), 3-18, 2016
Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecaná…
D Sargent, Q Shi, G Yothers, E Van Cutsem, J Cassidy, L Saltz, ...
European journal of cancer 47 (7), 990-996, 2011
Remote smartphone monitoring of Parkinson’s disease and individual response to therapy
L Omberg, E Chaibub Neto, TM Perumal, A Pratap, A Tediarjo, J Adams, ...
Nature biotechnology 40 (4), 480-487, 2022
Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials
CD Blanke, BM Bot, DM Thomas, A Bleyer, CH Kohne, MT Seymour, ...
Journal of clinical oncology 29 (20), 2781, 2011
Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancerá…
A De Gramont, J Hubbard, Q Shi, MJ O'Connell, M Buyse, J Benedetti, ...
Journal of clinical oncology 28 (3), 460, 2010
Differential gene expression profiling of matched primary renal cell carcinoma and metastases reveals upregulation of extracellular matrix genes
TH Ho, DJ Serie, M Parasramka, JC Cheville, BM Bot, W Tan, L Wang, ...
Annals of Oncology 28 (3), 604-610, 2017
A large dataset of protein dynamics in the mammalian heart proteome
E Lau, Q Cao, D Ng, BJ Bleakley, TU Dincer, BM Bot, D Wang, DA Liem, ...
Scientific data 3 (1), 1-15, 2016
Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from theá…
Q Shi, T Andre, A Grothey, G Yothers, SR Hamilton, BM Bot, DG Haller, ...
Journal of clinical oncology 31 (29), 3656, 2013
The Mole Mapper Study, mobile phone skin imaging and melanoma risk data collected using ResearchKit
DE Webster, C Suver, M Doerr, E Mounts, L Domenico, T Petrie, ...
Scientific data 4 (1), 1-8, 2017
Detecting the impact of subject characteristics on machine learning-based diagnostic applications
E Chaibub Neto, A Pratap, TM Perumal, M Tummalacherla, P Snyder, ...
NPJ digital medicine 2 (1), 99, 2019
Formative evaluation of participant experience with mobile eConsent in the app-mediated Parkinson mPower study: a mixed methods study
M Doerr, AM Truong, BM Bot, J Wilbanks, C Suver, LM Mangravite
JMIR mHealth and uHealth 5 (2), e6521, 2017
The system can't perform the operation now. Try again later.
Articles 1–20